US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Actuate Therapeutics Inc

2.37

+0.05002.16%

Volume:5.92K

Turnover:13.73K

Market Cap:55.09M

PE:-1.97

High:2.39

Open:2.31

Low:2.29

Close:2.32

52wk High:11.99

52wk Low:2.15

Shares:23.24M

Float Shares:9.28M

Volume Ratio:0.30

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2044

EPS(LYR):-3.2588

ROE:-296.04%

ROA:-95.25%

PB:5.04

PE(LYR):-0.73

Loading ...

Overview Company News Filings

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares

BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial

Actuate Therapeutics Reports Positive Phase 1 Results for Elraglusib in Pediatric Ewing Sarcoma and Neuroblastoma

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation

Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer

Actuate Therapeutics Signs $100M Sales Agreement

BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing

Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing

THOMSON REUTERS

Actuate Therapeutics Inc - May Sell Common Stock up to $100 Mln - SEC Filing

THOMSON REUTERS

Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACTU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACTU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":2.37,"timestamp":1774536381377,"preClose":2.32,"halted":0,"volume":5917,"delay":0,"changeRate":0.02155172413793115,"floatShares":9280300,"shares":23243328,"eps":-1.204351,"marketStatus":"Trading","change":0.05,"latestTime":"03-26 10:46:22 EDT","open":2.31,"high":2.3853,"low":2.29,"amount":13734.731519100002,"amplitude":0.041078,"askPrice":2.42,"askSize":300,"bidPrice":2.32,"bidSize":227,"shortable":3,"etf":0,"ttmEps":-1.204351,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":2.32,"postHourTrading":{"tag":"盘后","latestPrice":2.32,"preClose":2.32,"latestTime":"16:10 EDT","volume":4,"amount":9.28,"timestamp":1774469404984,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.303784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACTU\",,,,,undefined,":{"symbol":"ACTU","floatShares":9280300,"roa":"-95.25%","roe":"-296.04%","lyrEps":-3.258828,"volumeRatio":0.303784,"shares":23243328,"dividePrice":0,"high":2.3853,"amplitude":0.041078,"preClose":2.32,"low":2.29,"week52Low":2.15,"pbRate":"5.04","week52High":11.99,"institutionHeld":0,"latestPrice":2.37,"committee":-0.13852,"eps":-1.204351,"divideRate":0,"volume":5917,"delay":0,"ttmEps":-1.204351,"open":2.31,"prevYearClose":6.12,"prevWeekClose":2.35,"prevMonthClose":3.74,"prevQuarterClose":6.12,"fiveDayClose":2.5,"twentyDayClose":3.95,"sixtyDayClose":5.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACTU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ACTU","fiscalQuarterEnding":"2025/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-08-14","symbol":"ACTU","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-15","symbol":"ACTU","fiscalQuarterEnding":"2025/03","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACTU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACTU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1756180800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACTU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACTU","date":"2026-03-25","current":-1.926349,"percent":1,"low":-9.225925,"twenty":-6.610668,"median":-5.760243,"eighty":-4.881955,"high":-2.129676,"avg":-5.734156,"sd":1.120077,"marketCap":51367754},"quantilePoints":[{"date":"2024-07-25","current":-6.211408,"twenty":-6.211408,"median":-6.211408,"eighty":-6.211408,"marketCap":172493433},{"date":"2024-08-09","current":-5.505609,"twenty":-6.211408,"median":-6.211408,"eighty":-6.070248,"marketCap":152893088},{"date":"2024-08-16","current":-5.987349,"twenty":-6.211408,"median":-6.167236,"eighty":-5.841451,"marketCap":166271233},{"date":"2024-08-23","current":-5.560665,"twenty":-6.211408,"median":-5.987349,"eighty":-5.556536,"marketCap":154422018},{"date":"2024-08-30","current":-5.540019,"twenty":-6.211408,"median":-5.870355,"eighty":-5.533137,"marketCap":153848669},{"date":"2024-09-06","current":-5.608839,"twenty":-6.158401,"median":-5.624324,"eighty":-5.529008,"marketCap":155759833},{"date":"2024-09-13","current":-5.512491,"twenty":-6.078798,"median":-5.608839,"eighty":-5.512491,"marketCap":153084204},{"date":"2024-09-20","current":-5.03075,"twenty":-6.012125,"median":-5.608839,"eighty":-5.509738,"marketCap":139706059},{"date":"2024-09-27","current":-4.249491,"twenty":-5.950186,"median":-5.560665,"eighty":-5.486339,"marketCap":122463357},{"date":"2024-10-04","current":-5.056014,"twenty":-5.921282,"median":-5.540019,"eighty":-5.041842,"marketCap":145706004},{"date":"2024-10-11","current":-4.981461,"twenty":-5.86072,"median":-5.519373,"eighty":-4.824223,"marketCap":143557524},{"date":"2024-10-18","current":-4.920464,"twenty":-5.785018,"median":-5.512491,"eighty":-4.844556,"marketCap":141799677},{"date":"2024-10-25","current":-5.774428,"twenty":-5.765917,"median":-5.512491,"eighty":-4.844556,"marketCap":166409538},{"date":"2024-11-01","current":-5.306781,"twenty":-5.809795,"median":-5.512491,"eighty":-4.893354,"marketCap":152932709},{"date":"2024-11-08","current":-5.937088,"twenty":-5.927371,"median":-5.540019,"eighty":-4.957062,"marketCap":171097131},{"date":"2024-11-15","current":-5.958745,"twenty":-5.939799,"median":-5.550342,"eighty":-5.011034,"marketCap":169534600},{"date":"2024-11-22","current":-6.164693,"twenty":-5.973458,"median":-5.595075,"eighty":-5.037775,"marketCap":175394091},{"date":"2024-11-29","current":-5.581175,"twenty":-6.024512,"median":-5.608839,"eighty":-5.04517,"marketCap":158792200},{"date":"2024-12-06","current":-6.144098,"twenty":-6.055165,"median":-5.638088,"eighty":-5.051947,"marketCap":174808142},{"date":"2024-12-13","current":-5.917556,"twenty":-6.037784,"median":-5.643249,"eighty":-5.107523,"marketCap":168362702},{"date":"2024-12-20","current":-4.647547,"twenty":-6.017783,"median":-5.638088,"eighty":-5.04517,"marketCap":132229175},{"date":"2024-12-27","current":-6.068584,"twenty":-6.019156,"median":-5.638088,"eighty":-5.043814,"marketCap":172659662},{"date":"2025-01-03","current":-5.718473,"twenty":-6.013664,"median":-5.622603,"eighty":-5.049236,"marketCap":162698527},{"date":"2025-01-10","current":-5.697878,"twenty":-5.992612,"median":-5.622603,"eighty":-5.054658,"marketCap":162112578},{"date":"2025-01-17","current":-5.917556,"twenty":-5.969958,"median":-5.636367,"eighty":-5.146627,"marketCap":168362702},{"date":"2025-01-24","current":-6.940428,"twenty":-6.032033,"median":-5.643249,"eighty":-5.178584,"marketCap":197464839},{"date":"2025-01-31","current":-6.199017,"twenty":-6.064465,"median":-5.677284,"eighty":-5.209185,"marketCap":176370673},{"date":"2025-02-07","current":-6.047989,"twenty":-6.091559,"median":-5.691423,"eighty":-5.241176,"marketCap":172073713},{"date":"2025-02-14","current":-5.327173,"twenty":-6.072917,"median":-5.687582,"eighty":-5.255778,"marketCap":151565495},{"date":"2025-02-21","current":-5.279119,"twenty":-6.065838,"median":-5.658037,"eighty":-5.254405,"marketCap":150198280},{"date":"2025-02-28","current":-4.970198,"twenty":-6.060665,"median":-5.639808,"eighty":-5.174772,"marketCap":141409044},{"date":"2025-03-07","current":-4.771115,"twenty":-6.057666,"median":-5.608839,"eighty":-5.040292,"marketCap":135744870},{"date":"2025-03-14","current":-5.189762,"twenty":-6.053039,"median":-5.581175,"eighty":-5.033989,"marketCap":141604361},{"date":"2025-03-21","current":-4.831847,"twenty":-6.048768,"median":-5.560665,"eighty":-5.014488,"marketCap":131838543},{"date":"2025-03-28","current":-5.655051,"twenty":-6.042497,"median":-5.560665,"eighty":-5.033989,"marketCap":154299924},{"date":"2025-04-04","current":-4.932064,"twenty":-6.028767,"median":-5.540019,"eighty":-4.987939,"marketCap":134572972},{"date":"2025-04-11","current":-5.483252,"twenty":-6.017783,"median":-5.519391,"eighty":-4.984609,"marketCap":149612331},{"date":"2025-04-17","current":-5.726634,"twenty":-6.012291,"median":-5.540019,"eighty":-4.990995,"marketCap":156253088},{"date":"2025-04-25","current":-6.406672,"twenty":-6.045243,"median":-5.553757,"eighty":-4.998855,"marketCap":174808142},{"date":"2025-05-02","current":-7.537682,"twenty":-6.061192,"median":-5.567445,"eighty":-5.009067,"marketCap":205668127},{"date":"2025-05-09","current":-7.408833,"twenty":-6.107591,"median":-5.601957,"eighty":-5.032369,"marketCap":202152432},{"date":"2025-05-16","current":-8.179286,"twenty":-6.139979,"median":-5.636367,"eighty":-5.039569,"marketCap":206987413},{"date":"2025-05-23","current":-7.830407,"twenty":-6.178422,"median":-5.644452,"eighty":-5.043814,"marketCap":198158566},{"date":"2025-05-30","current":-8.194792,"twenty":-6.211408,"median":-5.662735,"eighty":-5.049236,"marketCap":207379806},{"date":"2025-06-06","current":-7.047366,"twenty":-6.281396,"median":-5.690843,"eighty":-5.056014,"marketCap":178342709},{"date":"2025-06-13","current":-6.675228,"twenty":-6.406672,"median":-5.69465,"eighty":-5.089546,"marketCap":168925272},{"date":"2025-06-20","current":-5.806906,"twenty":-6.42894,"median":-5.722554,"eighty":-5.141086,"marketCap":146951253},{"date":"2025-06-27","current":-4.512175,"twenty":-6.410449,"median":-5.697878,"eighty":-5.08284,"marketCap":114186421},{"date":"2025-07-03","current":-5.109147,"twenty":-6.389172,"median":-5.691014,"eighty":-5.046525,"marketCap":129293559},{"date":"2025-07-11","current":-4.791279,"twenty":-6.365148,"median":-5.677284,"eighty":-5.035608,"marketCap":121249498},{"date":"2025-07-18","current":-4.853302,"twenty":-6.320988,"median":-5.645656,"eighty":-4.991444,"marketCap":122819071},{"date":"2025-07-25","current":-5.419262,"twenty":-6.287654,"median":-5.638088,"eighty":-4.976956,"marketCap":137141423},{"date":"2025-08-01","current":-5.620836,"twenty":-6.265937,"median":-5.628589,"eighty":-4.986182,"marketCap":142242535},{"date":"2025-08-08","current":-6.527901,"twenty":-6.287654,"median":-5.632466,"eighty":-4.991444,"marketCap":165196967},{"date":"2025-08-15","current":-6.908485,"twenty":-6.414227,"median":-5.639808,"eighty":-4.995735,"marketCap":170525437},{"date":"2025-08-22","current":-6.442036,"twenty":-6.458702,"median":-5.650353,"eighty":-5.00125,"marketCap":159011858},{"date":"2025-08-29","current":-6.908485,"twenty":-6.483225,"median":-5.670419,"eighty":-5.019908,"marketCap":170525437},{"date":"2025-09-05","current":-7.328709,"twenty":-6.512404,"median":-5.690843,"eighty":-5.033989,"marketCap":180898030},{"date":"2025-09-12","current":-5.859066,"twenty":-6.574176,"median":-5.69465,"eighty":-5.040292,"marketCap":144622132},{"date":"2025-09-19","current":-6.375067,"twenty":-6.549229,"median":-5.726634,"eighty":-5.04517,"marketCap":157358843},{"date":"2025-09-26","current":-6.175411,"twenty":-6.549229,"median":-5.729418,"eighty":-5.051947,"marketCap":152430635},{"date":"2025-10-03","current":-6.212557,"twenty":-6.533707,"median":-5.754096,"eighty":-5.069427,"marketCap":153347511},{"date":"2025-10-10","current":-7.512643,"twenty":-6.537578,"median":-5.770478,"eighty":-5.097386,"marketCap":185438171},{"date":"2025-10-17","current":-7.24334,"twenty":-6.589924,"median":-5.79172,"eighty":-5.109147,"marketCap":178790820},{"date":"2025-10-24","current":-6.732591,"twenty":-6.670885,"median":-5.814177,"eighty":-5.112248,"marketCap":166183775},{"date":"2025-10-31","current":-6.110407,"twenty":-6.6744,"median":-5.859066,"eighty":-5.12,"marketCap":150826102},{"date":"2025-11-07","current":-5.785385,"twenty":-6.670885,"median":-5.869501,"eighty":-5.13638,"marketCap":142803437},{"date":"2025-11-14","current":-5.536933,"twenty":-6.66337,"median":-5.85039,"eighty":-5.154603,"marketCap":136670768},{"date":"2025-11-21","current":-5.868654,"twenty":-6.637844,"median":-5.836285,"eighty":-5.160645,"marketCap":141551867},{"date":"2025-11-28","current":-7.352682,"twenty":-6.647528,"median":-5.86386,"eighty":-5.168486,"marketCap":177346592},{"date":"2025-12-05","current":-7.082858,"twenty":-6.676544,"median":-5.869501,"eighty":-5.172026,"marketCap":170838460},{"date":"2025-12-12","current":-7.150314,"twenty":-6.706669,"median":-5.884194,"eighty":-5.183365,"marketCap":172465493},{"date":"2025-12-19","current":-6.764853,"twenty":-6.718803,"median":-5.896423,"eighty":-5.185781,"marketCap":163168162},{"date":"2025-12-26","current":-6.321572,"twenty":-6.721745,"median":-5.917556,"eighty":-5.189762,"marketCap":152476231},{"date":"2026-01-02","current":-5.897564,"twenty":-6.709975,"median":-5.917556,"eighty":-5.218313,"marketCap":142249167},{"date":"2026-01-09","current":-6.051748,"twenty":-6.706828,"median":-5.918043,"eighty":-5.231645,"marketCap":145968099},{"date":"2026-01-16","current":-5.12664,"twenty":-6.706347,"median":-5.916837,"eighty":-5.218313,"marketCap":123654504},{"date":"2026-01-23","current":-5.251915,"twenty":-6.701519,"median":-5.896423,"eighty":-5.230096,"marketCap":126676137},{"date":"2026-01-30","current":-4.567721,"twenty":-6.691045,"median":-5.884194,"eighty":-5.187481,"marketCap":110173374},{"date":"2026-02-06","current":-4.162986,"twenty":-6.680588,"median":-5.869501,"eighty":-5.163192,"marketCap":100411176},{"date":"2026-02-13","current":-4.085894,"twenty":-6.675886,"median":-5.86386,"eighty":-5.121593,"marketCap":98551710},{"date":"2026-02-20","current":-4.085894,"twenty":-6.6744,"median":-5.836285,"eighty":-5.109147,"marketCap":98551710},{"date":"2026-02-27","current":-3.806434,"twenty":-6.670885,"median":-5.810835,"eighty":-5.051947,"marketCap":91811145},{"date":"2026-03-06","current":-3.083693,"twenty":-6.66337,"median":-5.801368,"eighty":-5.014488,"marketCap":74378649},{"date":"2026-03-13","current":-2.457318,"twenty":-6.638594,"median":-5.7914,"eighty":-4.984609,"marketCap":59270486},{"date":"2026-03-20","current":-2.409136,"twenty":-6.610668,"median":-5.770478,"eighty":-4.925104,"marketCap":58108320},{"date":"2026-03-25","current":-2.129676,"twenty":-6.610668,"median":-5.760243,"eighty":-4.881955,"marketCap":51367754}],"updateTime":1774514810768},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACTU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602543575","title":"Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543575","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543575?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225500,"startTime":"0","endTime":"0","summary":"Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib combinatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2601800388","title":"Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601800388","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601800388?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:46","pubTimestamp":1767807983,"startTime":"0","endTime":"0","summary":"Todd S. Thomson, Director and 10% Owner of Actuate Therapeutics Inc., along with other reporting beneficial owners, reported a disposal of common shares of Actuate Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL64CDLh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Actuate Therapeutics Director Todd Thomson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2601968813","title":"BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601968813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601968813?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:24","pubTimestamp":1767709483,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial Jan 6 (Reuters) - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS ANNOUNCES POSITIVE PATIENT OUTCOMES FROM PHASE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA9RZTWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2601890719","title":"Actuate Therapeutics Reports Positive Phase 1 Results for Elraglusib in Pediatric Ewing Sarcoma and Neuroblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890719","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890719?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:45","pubTimestamp":1767707120,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced positive results from the phase 1 portion of its phase 1/2 clinical study  evaluating elraglusib, a GSK-3β inhibitor, in pediatric patients with relapsed or refractory cancers. Data from the trial showed two complete metabolic responses in patients with metastatic Ewing sarcoma and one complete response in a patient with metastatic neuroblastoma. Clinical responses and disease control were observed in 15 of 40 patients overall, including 10 of 19 patients treated with elraglusib in combination with cyclophosphamide and topotecan. Based on these results, Actuate plans to advance clinical development of elraglusib for Ewing sarcoma and potentially neuroblastoma, with additional clinical trials expected to begin in 2026. The company has been granted Rare Pediatric Disease Designations from the FDA for both indications. The results have already been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8PHs12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4588","BK4139","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","LU0314104364.USD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","ACTU"],"gpt_icon":0},{"id":"2601818471","title":"Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818471","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818471?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:45","pubTimestamp":1767707100,"startTime":"0","endTime":"0","summary":"Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213650/0/en/Actuate-Therapeutics-Announces-Positive-Patient-Outcomes-from-Phase-1-Trial-in-Difficult-to-Treat-Refractory-Pediatric-Cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","LU2413666699.HKD","BK4121","BK4135","BK4588","IE00B5TLWC47.USD","IE00BFXG0V08.USD","SD","BK4232","BK4139","CNS","IE00BYQQ9H92.USD","LU1721428933.USD","EWS","LU2413666426.HKD","CR","BK4533","LU1093756168.USD","BK4585","LU0347712357.USD","ETS","LU1093756325.SGD","LU2211817866.USD","BK4548","BK4213","PR","MTD","ACTU","BK4161"],"gpt_icon":0},{"id":"2592909049","title":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909049?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065527,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation. Actuate Therapeutics Inc. has announced that data from its Phase 2 clinical trial in metastatic pancreatic cancer will be featured in both an oral and poster presentation at the ASCO GI 2026 conference. The presentations are scheduled for January 9, 2026. The study evaluates the company’s lead investigational drug, elraglusib, a novel GSK-3β inhibitor targeting molecular pathways involved in tumor growth and resistance to conventional cancer therapies. The results are expected to be presented at the conference and have not yet been disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4SKPh1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","BK4588","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","LU2095319765.USD","BK4139","ACTU","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2591417156","title":"Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2591417156","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591417156?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:45","pubTimestamp":1765806314,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta  inhibitor, in combination with platinum chemotherapy , with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research , show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLtyvkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","BK4588","SG9999014021.USD","SG9999014039.USD","BK4139","SG9999014005.SGD","ACTU","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2587275846","title":"Actuate Therapeutics Signs $100M Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2587275846","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587275846?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:48","pubTimestamp":1764370127,"startTime":"0","endTime":"0","summary":"An update from Actuate Therapeutics, Inc. ( ($ACTU) ) is now available. On November 28, 2025, Actuate Therapeutics, Inc. entered into an At the Mar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actuate-therapeutics-signs-100m-sales-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"gpt_icon":0},{"id":"2587301758","title":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587301758","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587301758?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:28","pubTimestamp":1764368918,"startTime":"0","endTime":"0","summary":"BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC FilingNov 28  - Actuate Therapeutics Inc ACTU.O:ACTUATE THERAPEUTICS INC - MAY SELL COMMON STOCK UP TO $100 MILLION - SEC FILINGACTUATE THERAPEUTICS INC - ENTERS AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY AND CRAIG-HALLUM - SEC FILINGFurther company coverage: ACTU.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2587875889","title":"Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587875889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587875889?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:23","pubTimestamp":1764368587,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2587758893","title":"Actuate Therapeutics Inc - May Sell Common Stock up to $100 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2587758893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587758893?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:23","pubTimestamp":1764368587,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40LI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACTU","BK4139"],"gpt_icon":0},{"id":"2584943964","title":"Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584943964","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584943964?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:42","pubTimestamp":1763552520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 06:42 ET (11:42 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0},{"id":"2583507537","title":"Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583507537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583507537?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:45","pubTimestamp":1763131515,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $25.00. Lowe covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-actuate-therapeutics-inc-actu-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACTU"],"gpt_icon":0},{"id":"2583548422","title":"Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548422","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583548422?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:44","pubTimestamp":1763073896,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.07 percent. This is a 54.55 percent increase over losses of $(0.55) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853453/actuate-therapeutics-q3-eps-0-25-beats-0-28-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}]}}